Genocea Biosciences Initiates Phase 1 Study Of Vaccine Candidate GEN-004 To Prevent Infections Caused By Pneumococcus
12/5/2013 9:44:13 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.
Help employers find you! Check out all the jobs and post your resume.
comments powered by